Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Equillium Inc EQ

Healthcare Biotechnology
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL... see more

Recent & Breaking News (NDAQ:EQ)

METACRINE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Metacrine Inc. - MTCR

PR Newswire November 11, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, STR, MNRL, STOR

PR Newswire November 10, 2022

Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata

Business Wire November 10, 2022

Equillium to Present at Two Upcoming Investor Conferences

Business Wire November 8, 2022

Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit

Business Wire November 3, 2022

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Business Wire November 2, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, RCKT, RMED, RCOR

PR Newswire October 28, 2022

INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of Equillium, Inc. - EQ

PR Newswire October 27, 2022

Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference

Business Wire October 26, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNBE, CYBE, EQ, MNRL, RMED

PR Newswire October 18, 2022

Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis

Business Wire September 27, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, MTCR, STOR, RCKT

PR Newswire September 26, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ECOM, SGFY, EQ, MTCR

PR Newswire September 19, 2022

Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022

Business Wire September 15, 2022

EQ Stock Alert: Halper Sadeh LLP is Investigating Whether the Merger of Equillium, Inc. is Fair to Shareholders

Business Wire September 6, 2022

Equillium to Acquire Metacrine in All-Stock Transaction

Business Wire September 6, 2022

Equillium to Present at Two Upcoming Investor Conferences

Business Wire August 31, 2022

Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates

Business Wire August 15, 2022

Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit

Business Wire July 28, 2022

Equillium to Present at Two Upcoming Investor Conferences

Business Wire May 17, 2022